LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

Cocoon Biotech, Inc.

Founded in 2013, Cocoon Biotech is developing a drug-delivery platform with the first product targeting osteoarthritis. The technology is biocompatible silk fibroin loaded with a small molecule or protein drug that can be injected into the joint, designed to provide effective, long-lasting relief of pain and inflammation. Osteoarthritis causes significant joint pain that can lead to numerous other medical problems, including obesity and depression. Current treatment options, such as oral pain medications (e.g., Tylenol® and Advil®), injections of steroids or hyaluronic acid, and surgical knee replacement, have serious limitations. There is urgent need for new treatments that provide long-lasting pain relief at the disease site. Cocoon is committed to helping patients with osteoarthritis regain the freedom to live a healthy and productive life.

Pre-clinical testing has shown that Cocoon's platform silk fibroin drug delivery technology allows a wide variety of therapeutic agents to be injected into the body to provide long lasting treatment. Silk fibroin offers benefits that other drug delivery systems cannot match: biodegradable, drug release over months, and high drug loading. 

Cocoon has won numerous awards honoring biotech startups. The company is also the winner of two coveted LabCentral Golden Tickets sponsored by Amgen.

  • Ailis Tweed-Kent, MD Founder & CEO
  • Peter Mitchell, PhD Chief Scientific Officer
  • Steve Myers, MD Chief Medical Officer
  • Mike Santos Director of Formulation